Literature DB >> 34228795

Protein phosphatase 2A - structure, function and role in neurodevelopmental disorders.

Priyanka Sandal1, Chian Ju Jong1, Ronald A Merrill1, Jianing Song1, Stefan Strack1.   

Abstract

Neurodevelopmental disorders (NDDs), including intellectual disability (ID), autism and schizophrenia, have high socioeconomic impact, yet poorly understood etiologies. A recent surge of large-scale genome or exome sequencing studies has identified a multitude of mostly de novo mutations in subunits of the protein phosphatase 2A (PP2A) holoenzyme that are strongly associated with NDDs. PP2A is responsible for at least 50% of total Ser/Thr dephosphorylation in most cell types and is predominantly found as trimeric holoenzymes composed of catalytic (C), scaffolding (A) and variable regulatory (B) subunits. PP2A can exist in nearly 100 different subunit combinations in mammalian cells, dictating distinct localizations, substrates and regulatory mechanisms. PP2A is well established as a regulator of cell division, growth, and differentiation, and the roles of PP2A in cancer and various neurodegenerative disorders, such as Alzheimer's disease, have been reviewed in detail. This Review summarizes and discusses recent reports on NDDs associated with mutations of PP2A subunits and PP2A-associated proteins. We also discuss the potential impact of these mutations on the structure and function of the PP2A holoenzymes and the etiology of NDDs.
© 2021. Published by The Company of Biologists Ltd.

Entities:  

Keywords:  zzm321990 De novo mutations; Intellectual disability; Neurodevelopmental disorders; PP2A; Regulatory subunits

Mesh:

Substances:

Year:  2021        PMID: 34228795      PMCID: PMC8277144          DOI: 10.1242/jcs.248187

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.235


  241 in total

1.  PPP2R2C, a gene disrupted in autosomal dominant intellectual disability.

Authors:  Liesbeth Backx; Joris Vermeesch; Elly Pijkels; Thomy de Ravel; Eve Seuntjens; Hilde Van Esch
Journal:  Eur J Med Genet       Date:  2010-06-23       Impact factor: 2.708

Review 2.  PP2A: the expected tumor suppressor.

Authors:  Veerle Janssens; Jozef Goris; Christine Van Hoof
Journal:  Curr Opin Genet Dev       Date:  2005-02       Impact factor: 5.578

3.  Differential expression of the B'beta regulatory subunit of protein phosphatase 2A modulates tyrosine hydroxylase phosphorylation and catecholamine synthesis.

Authors:  Amit Saraf; David M Virshup; Stefan Strack
Journal:  J Biol Chem       Date:  2006-11-02       Impact factor: 5.157

Review 4.  Protein kinase biochemistry and drug discovery.

Authors:  Phillip A Schwartz; Brion W Murray
Journal:  Bioorg Chem       Date:  2011-08-03       Impact factor: 5.275

5.  Kelch-like protein 42 is a profibrotic ubiquitin E3 ligase involved in systemic sclerosis.

Authors:  Travis B Lear; Karina C Lockwood; Mads Larsen; Ferhan Tuncer; Jason R Kennerdell; Christina Morse; Eleanor Valenzi; Tracy Tabib; Michael J Jurczak; Daniel J Kass; John W Evankovich; Toren Finkel; Robert Lafyatis; Yuan Liu; Bill B Chen
Journal:  J Biol Chem       Date:  2020-02-17       Impact factor: 5.157

6.  Mice lacking phosphatase PP2A subunit PR61/B'delta (Ppp2r5d) develop spatially restricted tauopathy by deregulation of CDK5 and GSK3beta.

Authors:  Justin V Louis; Ellen Martens; Peter Borghgraef; Caroline Lambrecht; Ward Sents; Sari Longin; Karen Zwaenepoel; Robert Pijnenborg; Isabelle Landrieu; Guy Lippens; Birgit Ledermann; Jürgen Götz; Fred Van Leuven; Jozef Goris; Veerle Janssens
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-11       Impact factor: 11.205

7.  Reduced Expression of the PP2A Methylesterase, PME-1, or the PP2A Methyltransferase, LCMT-1, Alters Sensitivity to Beta-Amyloid-Induced Cognitive and Electrophysiological Impairments in Mice.

Authors:  Agnieszka Staniszewski; Hong Zhang; Kesava Asam; Rose Pitstick; Michael P Kavanaugh; Ottavio Arancio; Russell E Nicholls
Journal:  J Neurosci       Date:  2020-04-27       Impact factor: 6.167

8.  Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms.

Authors:  G A Calin; M G di Iasio; E Caprini; I Vorechovsky; P G Natali; G Sozzi; C M Croce; G Barbanti-Brodano; G Russo; M Negrini
Journal:  Oncogene       Date:  2000-02-24       Impact factor: 9.867

9.  DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources.

Authors:  Helen V Firth; Shola M Richards; A Paul Bevan; Stephen Clayton; Manuel Corpas; Diana Rajan; Steven Van Vooren; Yves Moreau; Roger M Pettett; Nigel P Carter
Journal:  Am J Hum Genet       Date:  2009-04-02       Impact factor: 11.025

10.  Division of labour between PP2A-B56 isoforms at the centromere and kinetochore.

Authors:  Giulia Vallardi; Lindsey A Allan; Lisa Crozier; Adrian T Saurin
Journal:  Elife       Date:  2019-03-04       Impact factor: 8.140

View more
  4 in total

1.  PPP2R5D promotes hepatitis C virus infection by binding to viral NS5B and enhancing viral RNA replication.

Authors:  Muhammad Ikram Anwar; Ni Li; Qing Zhou; Mingxiao Chen; Chengguang Hu; Tao Wu; Haihang Chen; Yi-Ping Li; Yuanping Zhou
Journal:  Virol J       Date:  2022-07-14       Impact factor: 5.913

Review 2.  Targeting protein phosphatases for the treatment of inflammation-related diseases: From signaling to therapy.

Authors:  Jie Pan; Lisha Zhou; Chenyang Zhang; Qiang Xu; Yang Sun
Journal:  Signal Transduct Target Ther       Date:  2022-06-04

3.  Genetic Variant of PP2A Subunit Gene Confers an Increased Risk of Primary Liver Cancer in Chinese.

Authors:  Youxin Wang; Qiuyue Huang; Xinglei Huang; Huiliu Zhao; Bin Guan; Kechen Ban; Xuefeng Zhu; Zhixing Ma; Yanmei Tang; Zhaohui Su; Qingqing Nong
Journal:  Pharmgenomics Pers Med       Date:  2021-12-01

4.  Arrestin Facilitates Rhodopsin Dephosphorylation in Vivo.

Authors:  Chia-Ling Hsieh; Yun Yao; Vsevolod V Gurevich; Jeannie Chen
Journal:  J Neurosci       Date:  2022-03-24       Impact factor: 6.709

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.